Cargando…

A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients

Detalles Bibliográficos
Autores principales:	Cortellini, Alessio, Ficorella, Corrado, Crisci, Roberto, Divisi, Duilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656359/ https://www.ncbi.nlm.nih.gov/pubmed/33209443 http://dx.doi.org/10.21037/jtd-20-1733

Ejemplares similares

Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report
por: Wu, Han, et al.
Publicado: (2022)

Lobectomy versus sublobar resection in patients with non-small cell lung cancer: a systematic review
por: Divisi, Duilio, et al.
Publicado: (2020)

Videothoracoscopy in Pleural Empyema Following Methicillin-Resistant Staphylococcus aureus (MRSA) Lung Infection
por: Divisi, Duilio, et al.
Publicado: (2009)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Is percutaneous tracheostomy the best method in the management of patients with prolonged mechanical ventilation?
por: Divisi, Duilio, et al.
Publicado: (2015)

Multiple Endocrine Neoplasia with Pulmonary Localization: A New Protocol of Approach
por: Divisi, Duilio, et al.
Publicado: (2008)

Right Diaphragm Spontaneous Rupture: A Surgical Approach
por: Divisi, Duilio, et al.
Publicado: (2011)

Management of Bronchopleural Fistula Complicated by Skin Wound Necrosis after Thoracomyoplasty
por: Divisi, Duilio, et al.
Publicado: (2017)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Case Report: A New Tool for Anterior Chest Wall Reconstruction After Sternal Resection for Primary Or Secondary Tumors
por: Divisi, Duilio, et al.
Publicado: (2021)

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
por: Giuliani, Jacopo, et al.
Publicado: (2021)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Diagnostic methods to localize pulmonary nodules and management of pleural infection after lobectomy
por: Divisi, Duilio, et al.
Publicado: (2022)

Family history of cancer and DNA damage response genes: Two sides of the same coin?
por: Cortellini, Alessio, et al.
Publicado: (2018)

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
por: Patel, Sandip, et al.
Publicado: (2023)

Video-assisted thoracoscopic sympathectomy versus modified Wittmoser method in surgical management of primary hyperhidrosis
por: Divisi, Duilio, et al.
Publicado: (2020)

Prolonged air leak after video-assisted thoracic anatomical pulmonary resections: a clinical predicting model based on data from the Italian VATS group registry, a machine learning approach
por: Divisi, Duilio, et al.
Publicado: (2022)

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
por: Napoleoni, Luca, et al.
Publicado: (2019)

Multidisciplinary and real life data: practical management of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)
por: D’Incecco, Armida, et al.
Publicado: (2022)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Cancer Care After Natural Disaster: Different Countries, Similar Problems
por: Verna, Lucilla, et al.
Publicado: (2019)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
por: Parisi, Alessandro, et al.
Publicado: (2019)

Endobronchial Ultrasound/Transbronchial Needle Aspiration-Biopsy for Systematic Mediastinal lymph Node Staging of Non-Small Cell Lung Cancer in Patients Eligible for Surgery: A Prospective Multicenter Study
por: Divisi, Duilio, et al.
Publicado: (2023)

Are CONSORT checklists submitted by authors adequately reflecting what information is actually reported in published papers?
por: Blanco, David, et al.
Publicado: (2018)

Is It Possible to Establish a Reliable Correlation between Maximum Standardized Uptake Value of 18-Fluorine Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Histological Types of Non-Small Cell Lung Cancer? Analysis of the Italian VATS Group Database
por: Divisi, Duilio, et al.
Publicado: (2021)

Chest wall reconstruction with implantable cross-linked porcine dermal collagen matrix: Evaluation of clinical outcomes
por: Gonfiotti, Alessandro, et al.
Publicado: (2022)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
por: Takeda, Masayuki, et al.
Publicado: (2019)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

“Vessels in the Storm”: Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer
por: Angelucci, Adriano, et al.
Publicado: (2018)

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
por: Verhoek, Andre, et al.
Publicado: (2023)

The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
por: Skupin-Mrugalska, Paulina, et al.
Publicado: (2020)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Finding chinks in the osimertinib resistance armor
por: Leal, Jose Luis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rsrbumtuc28b9hbb9o1gu9gdmb